参考文献/References:
[1] Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis[J]. Nat Rev Immunol, 2010,10(1):36-46.
[2] Lin J, Li H, Yang M, et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development[J]. Cell Rep,2013,3(1):200-210.
[3] Galluzzi L, Vitale I, Abrams JM, et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012[J]. Cell Death Differ,2012,19(1):107-120.
[4] Suzanne M, Steller H. Shaping organisms with apoptosis[J]. Cell Death Differ,2013,20(5):669-675.
[5] Taylor RC, Cullen SP, Martin SJ. Apoptosis:controlled demolition at the cellular level[J]. Nat Rev Mol Cell Biol,2008,9(3):231-241.
[6] Yang YP, Liang ZQ, Gu ZL, et al. Molecular mechanism and regulation of autophagy[J]. Acta Pharmacol Sin,2005,26(12):1421-1434.
[7] Mei Y, Thompson MD, Cohen RA, et al. Autophagy and oxidative stress in cardiovascular diseases[J]. Biochim Biophys Acta,2015,1852(2):243-251.
[8] Kitanaka C, Kuchino Y. Caspase-independent programmed cell death with necrotic morphology[J]. Cell Death Differ,1999,6(6):508-515.
[9] Xu Y, Huang S, Liu ZG, et al. Poly(ADPribose)polymerase-1 signalling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation[J]. J Biol Chem,2006,281(13):8788-8795.
[10] Vandenabeele P, Galluzzi L, Vanden Berghe T, et al. Molecular mechanisms of necroptosis:an ordered cellular explosion[J].Nat Rev Mol Cell Biol,2010, 11(10):700-714.
[11] Degterev A, Huang Z, Boyce M, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury[J]. Nat Chem Biol,2005,1(2):112-119.
[12] Formigli L, Papucci L, Tani A, et al. Aponecrosis:morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis[J]. J Cell Physiol,2000,182(1):41-49.
[13] Vercammen D, Beyaert R, Denecker G, et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor[J]. J Exp Med,1998,187(9):1477-1485.
[14] Cho YS. Perspectives on the therapeutic modulation of an alternative cell death, programmed necrosis(review)[J]. Int J Mol Med,2014,33(6):1401-1406.
[15] Khan N, Lawlor KE, Murphy JM, et al. More to life than death:molecular determinants of necroptotic and non-necroptotic RIP3 kinase signaling[J]. Curr Opin Immunol,2014,26:76-89.
[16] Zhou W, Yuan J. Necroptosis in health and diseases[J]. Semin Cell Dev Biol,2014,35:14-23.
[17] Gao X, Zhang H, Zhuang W, et al. PEDF and PEDF-derived peptide 44mer protect cardiomyocytes against hypoxia-induced apoptosis and necroptosis via anti-oxidative effect[J]. Sci Rep,2014,4:5637.
[18] Wallach D, Kang TB, Kovalenko A. Concepts of tissue injury and cell death in inflammation:a historical perspective[J]. Nat Rev Immunol,2014,14(1):51-59.
[19] Meng L, Jin W, Wang X. RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality[J]. Proc Natl Acad Sci USA,2015,112(35):11007-11012.
[20] Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation[J]. Nature,2015,517(7534):311-320.
[21] Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes[J]. Cell,2003,114(2):181-190.
[22] Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways[J]. Cell,2008,133(4):693-703.
[23] Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis:the release of damage-associated molecular patterns and its physiological relevance[J]. Immunity,2013,38(2):209-223.
[24] Oerlemans MI, Liu J, Arslan F, et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo[J]. Basic Res Cardiol,2012,107(4):270.
[25] Libby P. Inflammation in atherosclerosis[J]. Nature,2002,420(6917):868-874.
[26] Koch M, Zernecke A. The hemostatic system as a regulator of inflammation in atherosclerosis[J]. IUBMB Life,2014,66(11):735-744.
[27] Bao L, Li Y, Deng SX, et al. Sitosterol-containing lipoproteins trigger free sterol-induced caspase-independent death in ACAT-competent macrophages[J]. J Biol Chem,2006,281(44):33635-33649.
相似文献/References:
[1]胥雪莲,何川.前蛋白转化酶枯草溶菌素9与动脉粥样硬化[J].心血管病学进展,2016,(1):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
XU Xuelian,HE Chuan.Proprotein Convertase Subtilisin/Kexin Type 9 and Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(2):50.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.013]
[2]吴文芳,赵新湘,闫东.颈动脉斑块的核磁共振成像检测在冠心病中研究及应用进展[J].心血管病学进展,2016,(1):91.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.024]
WU Wenfang,ZHAO Xinxiang,YAN Dong.Magnetic Resonance Imaging Detection of Carotid Artery Plaque in
Coronary Artery Disease and Its Application[J].Advances in Cardiovascular Diseases,2016,(2):91.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.024]
[3]许利冬,综述,李为民,等.左主干解剖形态与左冠状动脉粥样硬化研究新进展[J].心血管病学进展,2016,(2):173.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.020]
XU Lidong,LI Weimin.New Progress Between Left Main Coronary Anatomy and Left Coronary
Atherosclerosis[J].Advances in Cardiovascular Diseases,2016,(2):173.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.020]
[4]陈芡茹,综述,叶飞,等.心血管疾病治疗新目标:脂蛋白相关磷脂酶A2[J].心血管病学进展,2016,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
CHEN Qianru,YE Fei.Novel Therapeutic Target of Cardiovascular Disease:Lipoprotein Associated
Phospholipase A2[J].Advances in Cardiovascular Diseases,2016,(2):188.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.024]
[5]蔡鹏,综述,王旭开,等.胰岛素清除率下降机制及其对大血管损伤作用的研究进展[J].心血管病学进展,2016,(3):292.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.020]
CAI Peng,WANG Xukai.Mechanism and Large Vascular Injury Effect of Insulin Clearance Decrease[J].Advances in Cardiovascular Diseases,2016,(2):292.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.020]
[6]刘欢,刘润冬,综述,等.血管内皮功能的评价及其临床价值[J].心血管病学进展,2016,(4):426.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.026]
LIU Huan,LIU Rundong,WANG Hongyu.Evaluation of Vascular Endothelial Function and Its Clinical Value[J].Advances in Cardiovascular Diseases,2016,(2):426.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.026]
[7]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(2):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[8]郭双 邢栋 吕勃.程序性坏死、细胞焦亡与心肌缺血再灌注损伤[J].心血管病学进展,2020,(12):1255.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.008]
GUO Shuang,XING Dong,LYU Bo.NecroptosisPyroptosis and Myocardial Ischemia-reperfusion Injury[J].Advances in Cardiovascular Diseases,2020,(2):1255.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.008]
[9]于洋杰 谢坤 高秀芳 施海明 李勇.非高密度脂蛋白胆固醇可以替代低密度脂蛋白胆固醇吗？[J].心血管病学进展,2021,(1):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
YU Yangjie,XIE Kun,GAO Xiufang,et al.Can LDL-C be Replaced by non-HDL-C[J].Advances in Cardiovascular Diseases,2021,(2):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[10]于洋杰 谢坤 施海明.血管生成素样蛋白3抑制剂研究进展[J].心血管病学进展,2021,(6):530.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.013]
YU Yangjie,XIE Kun,SHI Haiming.Angiopoietin-like Protein 3 Inhibitors[J].Advances in Cardiovascular Diseases,2021,(2):530.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.013]